Pfizer Inc.PFE announced top line data from two phase III induction studies on its rheumatoid arthritis (RA) drug, Xeljanz (tofacitinib 10 mg twice daily), from the Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) global development program. Both
Pfizer's Xeljanz Tops Phase III Ulcerative Colitis Studies
